INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $59,000 | – | 4,215 | +30007.1% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 14 | -99.1% | 0.00% | -100.0% |
| Q3 2021 | $22,000 | -73.8% | 1,513 | -55.2% | 0.00% | -75.0% |
| Q4 2020 | $84,000 | +833.3% | 3,381 | +1533.3% | 0.00% | +300.0% |
| Q3 2020 | $9,000 | 0.0% | 207 | +44.8% | 0.00% | -66.7% |
| Q3 2019 | $9,000 | -66.7% | 143 | -67.5% | 0.00% | -78.6% |
| Q1 2018 | $27,000 | +50.0% | 440 | +44.7% | 0.01% | 0.0% |
| Q4 2017 | $18,000 | -5.3% | 304 | -8.4% | 0.01% | +7.7% |
| Q3 2017 | $19,000 | 0.0% | 332 | +111.5% | 0.01% | -35.0% |
| Q2 2017 | $19,000 | -13.6% | 157 | -20.7% | 0.02% | -31.0% |
| Q1 2017 | $22,000 | +340.0% | 198 | +371.4% | 0.03% | +480.0% |
| Q4 2016 | $5,000 | +400.0% | 42 | +500.0% | 0.01% | +150.0% |
| Q1 2016 | $1,000 | -96.7% | 7 | -93.5% | 0.00% | -92.3% |
| Q1 2015 | $30,000 | – | 107 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |